<code id='F4AB46407B'></code><style id='F4AB46407B'></style>
    • <acronym id='F4AB46407B'></acronym>
      <center id='F4AB46407B'><center id='F4AB46407B'><tfoot id='F4AB46407B'></tfoot></center><abbr id='F4AB46407B'><dir id='F4AB46407B'><tfoot id='F4AB46407B'></tfoot><noframes id='F4AB46407B'>

    • <optgroup id='F4AB46407B'><strike id='F4AB46407B'><sup id='F4AB46407B'></sup></strike><code id='F4AB46407B'></code></optgroup>
        1. <b id='F4AB46407B'><label id='F4AB46407B'><select id='F4AB46407B'><dt id='F4AB46407B'><span id='F4AB46407B'></span></dt></select></label></b><u id='F4AB46407B'></u>
          <i id='F4AB46407B'><strike id='F4AB46407B'><tt id='F4AB46407B'><pre id='F4AB46407B'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:576
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Fight over Supreme Court dialysis ruling puts kidney patients at risk
          Fight over Supreme Court dialysis ruling puts kidney patients at risk

          AdobeAssoonassheheardtheSupremeCourtdecision,LaVarneBurtonbegantoworry.AsCEOofthenonprofitAmericanKi

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Apellis safety probe of eye disease drug centers on injection needle

          AlexHogan/STATApellisPharmaceuticalssaidTuesdaythatithadidentified“internalstructuralvariations”inat